Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8191 to 8205 of 8908 results

  1. Everolimus for the second-line treatment of advanced renal cell carcinoma (TA219)

    This guidance has been updated and replaced by NICE technology appraisal guidance 432.

    Withdrawn guidance

  2. Orlistat for the treatment of obesity in adults (TA22)

    This guidance has been replaced by NICE guideline CG43.

    Withdrawn guidance

  3. Trabectedin for the treatment of relapsed ovarian cancer (TA222)

    This guidance has been updated and replaced by NICE technology appraisal guidance 389.

    Withdrawn guidance

  4. Golimumab for the treatment of methotrexate-naive rheumatoid arthritis (terminated appraisal) (TA224)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Withdrawn guidance

  5. Endovascular stent–grafts for the treatment of abdominal aortic aneurysms (TA167)

    This guidance has been updated and replaced by NICE guideline NG156.

    Withdrawn guidance

  6. Laparoscopic surgery for colorectal cancer (TA17)

    This guidance has been replaced by NICE technology appraisal guidance 105. 

    Withdrawn guidance

  7. Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (TA172)

    This guidance has been updated and replaced by NICE technology appraisal guidance 473.

    Withdrawn guidance

  8. Zanamivir for the treatment of influenza in adults (TA15)

    This guidance has been replaced by NICE technology appraisal guidance 58 [Replaced by NICE technology appraisal guidance 168].

    Withdrawn guidance

  9. Cetuximab for the treatment of metastatic colorectal cancer following failure of oxaliplatin-containing chemotherapy (TA150)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 242.

    Withdrawn guidance

  10. Gefitinib for the second-line treatment of locally advanced or metastatic non-small-cell lung cancer (terminated appraisal) (TA175)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Withdrawn guidance

  11. Cetuximab for the first-line treatment of metastatic colorectal cancer (TA176)

    This guidance has been updated and replaced by NICE technology appraisal guidance 439.

    Withdrawn guidance

  12. Adalimumab for the treatment of psoriatic arthritis (TA125)

    This guidance has been updated and replaced by NICE technology appraisal guidance 199.

    Withdrawn guidance

  13. Rituximab for the treatment of rheumatoid arthritis (TA126)

    This guidance has been updated and replaced by NICE technology appraisal guidance 195.

    Withdrawn guidance

  14. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  15. Parent-training/education programmes in the management of children with conduct disorders (TA102)

    This guidance has been updated and replaced by NICE guideline CG158.

    Withdrawn guidance